Effects of human complement component 1 inactivator on neutrophil chemotaxis and chemotactic deactivation. 1980

R A Patrick, and J C Hollers, and D Y Liu, and B H Giese, and C W Smith

This study was undertaken to ascertain the relationship between complement-derived chemotactic factors and complement component 1 inactivator (C1INA) enhancement of neutrophil chemotaxis. Studies were also designed to determine whether the C1s- reactive or binding site on C1INA was functional in altering chemotactic responsiveness of neutrophilic leukocyes. Chemotaxis was assessed by determining cell migration in micropore filters. C1INA was found to enhance the chemotactic response to zymosan-activated plasma, C5a, and N-formyl-L-methionyl-L-phenylalanine and to bring the response of chemotactically deactivated cells to normal. In contrast, C1INA inhibited the chemotactic response to trypsin and EAC4oxy2-activated C3. Complexes of C1INA and C1s- failed to mediate the usual C1INA-enhanced response. Artificially produced C5-deficient plasma, when treated with zymosan, failed to support chemotaxis or to produce chemotactic deactivation. C1INA was without effect when this activated plasma was used as a source of chemotactic factors. We conclude from these data that C1INA enhancement of neutrophil chemotaxis to activated plasma is associated with C5-derived chemotactic fragments. The effects of C1INA are apparently related to the C1s- reactive or binding site(s) on the C1INA molecule. We suggest that C1INA may play a homeostatic role in neutrophil chemotaxis.

UI MeSH Term Description Entries
D009239 N-Formylmethionine Effective in the initiation of protein synthesis. The initiating methionine residue enters the ribosome as N-formylmethionyl tRNA. This process occurs in Escherichia coli and other bacteria as well as in the mitochondria of eucaryotic cells. N Formylmethionine,Formylmethionine, N
D009240 N-Formylmethionine Leucyl-Phenylalanine A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated. F-Met-Leu-Phe,N-Formyl-Methionyl-Leucyl-Phenylalanine,Formylmet-Leu-Phe,Formylmethionyl Peptide,Formylmethionyl-Leucyl-Phenylalanine,Formylmethionylleucylphenylalanine,N-Formylated Peptide,N-formylmethionyl-leucyl-phenylalanine,fMet-Leu-Phe,F Met Leu Phe,Formylmet Leu Phe,Formylmethionyl Leucyl Phenylalanine,Leucyl-Phenylalanine, N-Formylmethionine,N Formyl Methionyl Leucyl Phenylalanine,N Formylated Peptide,N Formylmethionine Leucyl Phenylalanine,N formylmethionyl leucyl phenylalanine,Peptide, Formylmethionyl,Peptide, N-Formylated,fMet Leu Phe
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D001790 Blood Physiological Phenomena Physiological processes and properties of the BLOOD. Blood Physiologic Processes,Blood Physiological Processes,Blood Physiology,Blood Physiological Concepts,Blood Physiological Phenomenon,Physiology, Blood,Blood Physiological Concept,Blood Physiological Phenomenas,Concept, Blood Physiological,Concepts, Blood Physiological,Phenomena, Blood Physiological,Phenomenon, Blood Physiological,Physiologic Processes, Blood,Physiological Concept, Blood,Physiological Concepts, Blood,Physiological Phenomenon, Blood,Processes, Blood Physiologic,Processes, Blood Physiological
D002634 Chemotaxis, Leukocyte The movement of leukocytes in response to a chemical concentration gradient or to products formed in an immunologic reaction. Leukotaxis,Leukocyte Chemotaxis
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003174 Complement C1 Inactivator Proteins Serum proteins that inhibit, antagonize, or inactivate COMPLEMENT C1 or its subunits. Complement 1 Esterase Inhibitors,Complement C1 Inactivating Proteins,Complement C1 Inhibiting Proteins,Complement C1 Inhibitor Proteins,Complement C1r Protease Inhibitor Proteins,Complement C1s Esterase Inhibitor Proteins,Complement Component 1 Inactivator Proteins
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D003182 Complement C5 C5 plays a central role in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C5 is cleaved by C5 CONVERTASE into COMPLEMENT C5A and COMPLEMENT C5B. The smaller fragment C5a is an ANAPHYLATOXIN and mediator of inflammatory process. The major fragment C5b binds to the membrane initiating the spontaneous assembly of the late complement components, C5-C9, into the MEMBRANE ATTACK COMPLEX. C5 Complement,Complement 5,Complement C5, Precursor,Complement Component 5,Precursor C5,Pro-C5,Pro-complement 5,C5, Complement,C5, Precursor,C5, Precursor Complement,Complement, C5,Component 5, Complement,Precursor Complement C5,Pro C5,Pro complement 5

Related Publications

R A Patrick, and J C Hollers, and D Y Liu, and B H Giese, and C W Smith
September 1981, Journal of immunology (Baltimore, Md. : 1950),
R A Patrick, and J C Hollers, and D Y Liu, and B H Giese, and C W Smith
January 1977, Infection and immunity,
R A Patrick, and J C Hollers, and D Y Liu, and B H Giese, and C W Smith
October 1980, British journal of experimental pathology,
R A Patrick, and J C Hollers, and D Y Liu, and B H Giese, and C W Smith
February 1987, The Journal of laboratory and clinical medicine,
R A Patrick, and J C Hollers, and D Y Liu, and B H Giese, and C W Smith
August 1979, Journal of immunology (Baltimore, Md. : 1950),
R A Patrick, and J C Hollers, and D Y Liu, and B H Giese, and C W Smith
January 1981, The Japanese journal of surgery,
R A Patrick, and J C Hollers, and D Y Liu, and B H Giese, and C W Smith
January 1991, Journal of immunology (Baltimore, Md. : 1950),
R A Patrick, and J C Hollers, and D Y Liu, and B H Giese, and C W Smith
May 2001, Journal of biochemical and biophysical methods,
R A Patrick, and J C Hollers, and D Y Liu, and B H Giese, and C W Smith
August 1981, The Journal of laboratory and clinical medicine,
Copied contents to your clipboard!